View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 4, 2019

Vertex to buy Semma Therapeutics for $950m

Vertex Pharmaceuticals will acquire all outstanding shares of biotechnology firm Semma Therapeutics for a cash sum of $950m.

Vertex Pharmaceuticals will acquire all outstanding shares of biotechnology firm Semma Therapeutics for a cash sum of $950m.

Semma has developed a technique to generate vast quantities of functional, insulin-producing human pancreatic beta cells from stem cells for the treatment of patients with type 1 diabetes.

In animal models, the investigational method was found to restore insulin secretion and ameliorate hypoglycaemia.

Semma also created a device to encapsulate and protect the pancreatic beta cells from the body’s immune system.

The islet cell-filled device’s implantation is said to enable durable therapy, while avoiding the requirement of continuous immunosuppression.

Vertex expects the acquisition to aid in the development of curative therapies for type 1 diabetes.

Vertex Pharmaceuticals chairman, president and CEO Jeffrey Leiden said: “We are excited to work with the talented scientists at Semma to build on their significant progress toward providing effective and potentially curative cell therapy options for people living with type 1 diabetes.

“We see a substantial opportunity to transform the treatment paradigm for type 1 diabetes, a speciality disease cared for by endocrinologists, both by advancing the development and manufacturing of the cells themselves, as well as through the highly innovative cell / device combination.”

Semma has demonstrated preclinical proof-of-concept of the cell / device system, where the company assessed human stem cell-derived islets (SC-islets) in non-human primates and pigs.

The approach demonstrated positive c-peptide release, a marker of insulin secretion and positive glycaemic control of experimentally induced diabetes.

Semma Therapeutics president and CEO Bastiano Sanna said: “Type 1 diabetes is a disease that afflicts millions of people worldwide and has no curative therapies available.

“Being a part of Vertex will allow the Semma team to rapidly and effectively advance our cell therapy and delivery approaches to patients who need them.”

The acquisition is scheduled for completion in the fourth quarter of this year, subject to customary closing conditions.

Following the closing of the transaction, Semma will operate as a separate subsidiary of Vertex. Sanna will serve as Semma’s president and the company’s founder Douglas Melton will continue as chair of its scientific advisory board.

In June, Vertex agreed to buy Exonics Therapeutics, which develops gene-editing therapies.

Cell & Gene Therapy Coverage on Pharmaceutical Technology supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology